06 Oct 2026, 08:47 IST
Molbio Diagnostics Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target INR 1,800
The report initiates coverage on Molbio Diagnostics with a BUY rating, CMP INR 1,503 and TP INR 1,800, citing its Truenat platform, 12,500+ devices in 90+ countries, and an estimated 23% revenue CAGR and 50% PAT CAGR over FY26-29.
From MOStMarketOutlook06102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.